COVID-19 is a new infectious disease, caused by the SARS-CoV-2 virus, which first appeared in December 2019 in the city of Wuhan and spread very quickly to the rest of the world. The emerging pandemic affected all components of transplant programs, which was reflected in the reduction of the total number of transplants globally. Due to the susceptibility of transplanted patients to infectious diseases, it was questioned the possibility of transmitting the infection to organ recipients, either from living or deceased donors, or during their stay in health care facilities. Another question was how to conduct screening for COVID-19 and minimize hospital stays. Also, an increasing number of COVID-19 positive patients in need of inpatient treatment require the allocation of resources to intensive care units, thus limiting resources and medical staff who can care for patients postoperatively. All of the above leads to a reduced number of organs for transplantation, changes in surgical practice and also to the increasing implementation of telemedicine in the follow-up of patients. The consequences that the COVID-19 pandemic will leave are a significant increase in waiting lists and, accordingly, a larger number of people who will have to replace their renal function with dialysis, which carries its own risks.